Detalhe da pesquisa
1.
Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Int Arch Allergy Immunol
; 181(8): 613-617, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32570256
2.
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
Clin Exp Allergy
; 54(4): 286-290, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084474
3.
RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.
Allergy
; 77(9): 2848-2852, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595723